Event to feature renowned leaders in the
field of immunotherapy and neuro-oncology
TORONTO and HOUSTON, Nov. 18,
2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or
"the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage
immuno-oncology company, today announced that it will host a
lunchtime seminar led by key opinion leaders ("KOL"'s) to highlight
the current treatment options for recurrent glioblastoma ("rGBM")
and the clinical benefits seen with MDNA55, an IL4 receptor
targeted therapy in this setting. In addition to the Principal
Investigators of the recently completed Phase 2b clinical trial, Dr. John Sampson and Dr. Santosh Kesari, the co-inventor of MDNA55 Dr.
Raj Puri, will also participate in the symposium. The event will
take place during the Society for Neuro-Oncology ("SNO") annual
meeting being held at the JW Marriott Desert Ridge Resort at 5350
E. Marriott Drive in Phoenix,
AZ.
The symposium is scheduled for Friday,
November 22 from 12:15 to 1:15 PM
MT in the Grand Sonoran Room G and will feature
presentations as follows:
- Raj Puri, MD, PhD – Director, Division of Cellular and
Gene Therapies, Center for Biologics Evaluation and Research,
FDA.
- John H. Sampson, MD, PhD,
MHSc, MBA – Robert H. and Gloria Wilkins Distinguished
Professor and Chair of Neurosurgery, Department of Neurosurgery,
Duke University School of Medicine
- Santosh Kesari, MD, PhD -
Director, Neuro-oncology, Pacific Neuroscience Institute; Chair and
Professor, Department of Translational Neurosciences and
Neurotherapeutics, John Wayne Cancer Institute
The panel will discuss the current unmet medical need for
treating individuals with rGBM, the most common and uniformly fatal
form of brain cancer, and the potential for an IL4 receptor
targeted therapy to combat this disease. The presentation will also
highlight key safety and efficacy data from the MDNA55 Phase
2b clinical trial and the positive
outcomes seen in patients enrolled in this study.
For information on this event, please send an email request to
chan@medicenna.com.
Medicenna intends to follow this event with a KOL call for
investors, analysts and business development professionals. Further
information on this event and the KOL call will be released as soon
as available.
About Medicenna Therapeutics Corp.
Medicenna is a
clinical stage immunotherapy company focused on oncology and the
development and commercialization of novel, highly selective
versions of IL-2, IL-4 and IL-13 Superkines and first in class
Empowered Cytokines™ (ECs) for the treatment of a broad range of
cancers. Supported by a US$14.1M
non-dilutive grant from CPRIT (Cancer Prevention and Research
Institute of Texas), Medicenna's
lead IL4-EC, MDNA55, has completed enrolling patients in a Phase
2b clinical trial for rGBM, the most
common and uniformly fatal form of brain cancer, at top-ranked
brain cancer centres in the US. MDNA55 has been studied in five
clinical trials involving 132 patients, including 112 adults with
rGBM. MDNA55 has demonstrated compelling efficacy and has obtained
Fast-Track and Orphan Drug status from the FDA and FDA/EMA
respectively. For more information, please visit
www.medicenna.com.
This news release contains forward-looking statements
relating to the future operations of the Company and other
statements that are not historical facts. Forward-looking
statements are often identified by terms such as "will", "may",
"should", "anticipate", "expects" and similar expressions. All
statements other than statements of historical fact, included in
this release, including, without limitation, statements related to
the Phase 2b clinical trial of MDNA55
for the treatment of rGBM and the future plans and objectives of
the Company, are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements.
Important factors that could cause actual results to differ
materially from the Company's expectations include the risks
detailed in the annual information form of the Company dated
June 24, 2019 and in other filings
made by the Company with the applicable securities regulators from
time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information (including, without
limitation, the ability of the Company to fully replicate these
interim data results) may prove to be incorrect. Events or
circumstances may cause actual results to differ materially from
those predicted, as a result of numerous known and unknown risks,
uncertainties, and other factors, many of which are beyond the
control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of
preparation, may prove to be incorrect and actual results may
differ materially from those anticipated. Forward-looking
statements contained in this news release are expressly qualified
by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news
release and the Company will update or revise publicly any of the
included forward-looking statements only as expressly required by
Canadian securities law.
View original
content:http://www.prnewswire.com/news-releases/medicenna-to-host-a-key-opinion-leader-symposium-on-mdna55-for-treatment-of-recurrent-glioblastoma-300959869.html
SOURCE Medicenna Therapeutics Corp.